• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Pegcetacoplan improved hemoglobin levels in eculizumab-treated paroxysmal nocturnal hemoglobinuria patients

byConstance Wu
March 25, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Pegcetacoplan was shown to reduce the change in hemoglobin level for the treatment of paroxysmal nocturnal hemoglobinuria compared to eculizumab.

2. Patients treated with pegcetacoplan experienced fewer transfusions and less fatigue.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder that results from aberrant hematopoietic clones that result in complement-mediated extra- and intravascular hemolysis and thrombosis. C5 inhibitors such as eculizumab help control intravascular hemolysis and are one of the standard treatments for PNH. However, extravascular hemolysis still occurs and is not targeted by C5 inhibition. Pegcetacoplan, a C3 inhibitor, is potentially effective for both extravascular and intravascular hemolysis in PNH. As such, this study compared pegcetacoplan to eculizumab in eculizumab-treated PNH patients. The study determined pegcetacoplan monotherapy had less hemoglobin loss and more transfusion-free patients. The study was limited by a small patient population. Nonetheless, this trial demonstrated that pegcetacoplan was superior to eculizumab in controlling hemoglobin loss and improved in key patient outcomes with a favorable adverse event profile.

Click here to read the study in the NEJM

Relevant Reading: Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

In-Depth [randomized controlled trial]: This was a multicenter, randomized, open-label trial of 80 adult patients with PNH. The inclusion criteria were patients treated with eculizumab therapy and hemoglobin levels lower than 10.5 g per deciliter. Patients not treated with eculizumab for at least three months prior to the study were excluded from the study. Patients were randomized in a 1:1 ratio to either pegcetacoplan monotherapy or eculizumab monotherapy, respectively. The primary endpoint was hemoglobin level change from baseline to week 16. The mean change was 2.37 g per deciliter in the pegcetacoplan group compared to -1.47 g per deciliter in the eculizumab group (mean difference, 3.84 g per deciliter; 95% confidence interval [CI], 2.33 to 5.34; P < 0.001). More patients in pegcetacoplan group (35 out of 41 patients, 85%) were transfusion-free compared to the eculizumab group (6 out of 39 patients, 15%) (P < 0.001). Furthermore, the change in lactate dehydrogenase level from baseline did not achieve noninferiority between pegcetacoplan monotherapy (-15±43 U per liter) and eculizumab monotherapy (-10±71 U per liter). The incidence of serious adverse events was similar between both groups. The most common adverse events in the pegcetacoplan group were injection site reactions and diarrhea; however, there were no reported cases of meningitis. Overall, pegcetacoplan was superior to eculizumab in key hematological parameters and clinical outcomes with a side effect profile favoring pegcetacoplan.

RELATED REPORTS

Pegcetacoplan improved hemoglobin levels in eculizumab-treated paroxysmal nocturnal hemoglobinuria patients

#VisualAbstract: Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

The PREVENT trial: eculizumab reduces relapse risk in patients with neuromyelitis optica and aquaporin-4 antibodies

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: EculizumabParoxysmal nocturnal hemoglobinuriapegcetacoplanpnh
Previous Post

Semaglutide 2.4 mg once a week decreases bodyweight in overweight or obese patients with type 2 diabetes

Next Post

Reinfection rates among patients previously testing positive for COVID-19

RelatedReports

Study explores effects of daily iron supplementation in 2- to 5-year-olds
All Specialties

Pegcetacoplan improved hemoglobin levels in eculizumab-treated paroxysmal nocturnal hemoglobinuria patients

March 18, 2021
#VisualAbstract: Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
StudyGraphics

#VisualAbstract: Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

September 9, 2019
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

The PREVENT trial: eculizumab reduces relapse risk in patients with neuromyelitis optica and aquaporin-4 antibodies

August 17, 2019
Complement mutation linked to poor response to eculizumab
Chronic Disease

Complement mutation linked to poor response to eculizumab

February 14, 2014
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

Reinfection rates among patients previously testing positive for COVID-19

#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

#VisualAbstract: Early discontinuation of endocrine therapy may increase risk of breast cancer recurrence in premenopausal women

#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.